FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995928704> ?p ?o ?g. }

• W2995928704 endingPage "500" @default.
• W2995928704 startingPage "494" @default.
• W2995928704 abstract "LATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC). To assess the correlation of prostate-specific antigen (PSA) kinetics with overall survival (OS) and radiological progression-free survival (rPFS). A post hoc analysis of data from 597 men receiving AAP + ADT and 602 receiving PBO + ADT. The associations of PSA-related outcomes (rates of confirmed 50% [PSA50] and 90% [PSA90] decline from baseline PSA [Prostate Cancer Working Group 2 criteria], rates of PSA < 0.2 ng/ml, median nadir PSA, time to PSA nadir [TPN], and time to PSA progression [TPP] with long-term outcomes [OS and rPFS]) were evaluated. Hazard ratios (HRs) were estimated using Cox proportional hazard model. Correlations of TPP with coprimary endpoints rPFS and OS were evaluated using Kendall’s tau (KT). AAP + ADT significantly delayed median TPP versus PBO + ADT (33.2 vs 7.4 mo; HR: 0.3, p < 0.001). TPP correlated with rPFS (KT = 0.921) and OS (KT = 0.666). In the AAP + ADT group, 91% had PSA50 and 79% had PSA90 responses (relative risk [RR]: 1.36 and 2.30, respectively; p < 0.001 for both comparisons vs PBO + ADT). Compared with nonresponders, PSA50 and PSA90 responders had reduced risk of death (RR: 0.44 and 0.12, respectively). At 6 mo, 40% receiving AAP + ADT and 6.5% receiving PBO + ADT achieved PSA ≤0.1 ng/ml, which was significantly associated with longer rPFS and OS. Median nadir PSA was 0.09 ng/ml with AAP + ADT versus 2.36 ng/ml with PBO + ADT. Median TPN (AAP + ADT, 6.4 mo; PBO + ADT, 3.8 mo) positively correlated with rPFS and OS. Superior PSA response dynamics with AAP + ADT versus ADT + PBO strongly correlated with long-term outcomes of rPFS and OS in high-risk mCSPC. We found that low prostate-specific antigen levels (≤0.1 ng/ml) after 6 mo may indicate a good long-term response to treatment. Our results need confirmation." @default.
• W2995928704 created "2019-12-26" @default.
• W2995928704 creator A5005231494 @default.
• W2995928704 creator A5007779528 @default.
• W2995928704 creator A5014625956 @default.
• W2995928704 creator A5015365593 @default.
• W2995928704 creator A5019977496 @default.
• W2995928704 creator A5023874099 @default.
• W2995928704 creator A5028207252 @default.
• W2995928704 creator A5028391998 @default.
• W2995928704 creator A5043791596 @default.
• W2995928704 creator A5060759473 @default.
• W2995928704 creator A5061992932 @default.
• W2995928704 creator A5062742458 @default.
• W2995928704 creator A5072514289 @default.
• W2995928704 creator A5084974200 @default.
• W2995928704 date "2020-04-01" @default.
• W2995928704 modified "2023-10-16" @default.
• W2995928704 title "Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study" @default.
• W2995928704 cites W1564427947 @default.
• W2995928704 cites W1856025141 @default.
• W2995928704 cites W2004787132 @default.
• W2995928704 cites W2007824082 @default.
• W2995928704 cites W2026102934 @default.
• W2995928704 cites W2037733927 @default.
• W2995928704 cites W2056534737 @default.
• W2995928704 cites W2063113306 @default.
• W2995928704 cites W2092860006 @default.
• W2995928704 cites W2112304044 @default.
• W2995928704 cites W2117783793 @default.
• W2995928704 cites W2125942853 @default.
• W2995928704 cites W2137467802 @default.
• W2995928704 cites W2142466432 @default.
• W2995928704 cites W2145608595 @default.
• W2995928704 cites W2150865892 @default.
• W2995928704 cites W2155679349 @default.
• W2995928704 cites W2166922670 @default.
• W2995928704 cites W2167331614 @default.
• W2995928704 cites W2168108459 @default.
• W2995928704 cites W2168242827 @default.
• W2995928704 cites W2171724045 @default.
• W2995928704 cites W2403880768 @default.
• W2995928704 cites W2501712293 @default.
• W2995928704 cites W2508767114 @default.
• W2995928704 cites W2620798309 @default.
• W2995928704 cites W2910463024 @default.
• W2995928704 cites W2921709383 @default.
• W2995928704 doi "https://doi.org/10.1016/j.eururo.2019.11.021" @default.
• W2995928704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31843335" @default.
• W2995928704 hasPublicationYear "2020" @default.
• W2995928704 type Work @default.
• W2995928704 sameAs 2995928704 @default.
• W2995928704 citedByCount "44" @default.
• W2995928704 countsByYear W29959287042020 @default.
• W2995928704 countsByYear W29959287042021 @default.
• W2995928704 countsByYear W29959287042022 @default.
• W2995928704 countsByYear W29959287042023 @default.
• W2995928704 crossrefType "journal-article" @default.
• W2995928704 hasAuthorship W2995928704A5005231494 @default.
• W2995928704 hasAuthorship W2995928704A5007779528 @default.
• W2995928704 hasAuthorship W2995928704A5014625956 @default.
• W2995928704 hasAuthorship W2995928704A5015365593 @default.
• W2995928704 hasAuthorship W2995928704A5019977496 @default.
• W2995928704 hasAuthorship W2995928704A5023874099 @default.
• W2995928704 hasAuthorship W2995928704A5028207252 @default.
• W2995928704 hasAuthorship W2995928704A5028391998 @default.
• W2995928704 hasAuthorship W2995928704A5043791596 @default.
• W2995928704 hasAuthorship W2995928704A5060759473 @default.
• W2995928704 hasAuthorship W2995928704A5061992932 @default.
• W2995928704 hasAuthorship W2995928704A5062742458 @default.
• W2995928704 hasAuthorship W2995928704A5072514289 @default.
• W2995928704 hasAuthorship W2995928704A5084974200 @default.
• W2995928704 hasConcept C121608353 @default.
• W2995928704 hasConcept C126322002 @default.
• W2995928704 hasConcept C126894567 @default.
• W2995928704 hasConcept C143998085 @default.
• W2995928704 hasConcept C207103383 @default.
• W2995928704 hasConcept C2775832370 @default.
• W2995928704 hasConcept C2776551883 @default.
• W2995928704 hasConcept C2776694085 @default.
• W2995928704 hasConcept C2777899217 @default.
• W2995928704 hasConcept C2778720950 @default.
• W2995928704 hasConcept C2779322244 @default.
• W2995928704 hasConcept C2779466945 @default.
• W2995928704 hasConcept C2780192828 @default.
• W2995928704 hasConcept C2780739268 @default.
• W2995928704 hasConcept C2781406297 @default.
• W2995928704 hasConcept C44249647 @default.
• W2995928704 hasConcept C50382708 @default.
• W2995928704 hasConcept C61367390 @default.
• W2995928704 hasConcept C71924100 @default.
• W2995928704 hasConceptScore W2995928704C121608353 @default.
• W2995928704 hasConceptScore W2995928704C126322002 @default.
• W2995928704 hasConceptScore W2995928704C126894567 @default.
• W2995928704 hasConceptScore W2995928704C143998085 @default.
• W2995928704 hasConceptScore W2995928704C207103383 @default.
• W2995928704 hasConceptScore W2995928704C2775832370 @default.
• W2995928704 hasConceptScore W2995928704C2776551883 @default.

• next